By , ANKARA (Reuters) -A COVID-19 vaccine developed by China’s Sinovac Biotech is 91.25% effective, according to interim data from a late-stage trial in Turkey, a potentially much better result than reported from a separate trial of the vaccine in Brazil.Researchers in Brazil, which is also running a final Phase III trial of the vaccine, said on Wednesday the shot was more than 50% effective, but withheld full results at the company’s request, raising questions about transparency.Turkish researchers said on Thursday no major side-effects were seen during their trial, apart from one person...…By , ANKARA (Reuters) -A COVID-19 vaccine developed by China’s Sinovac Biotech is 91.25% effective, according to interim data from a late-stage trial in Turkey, a potentially much better result than reported from a separate trial of the vaccine in Brazil.Researchers in Brazil, which is also running a final Phase III trial of the vaccine, said on Wednesday the shot was more than 50% effective, but withheld full results at the company’s request, raising questions about transparency.Turkish researchers said on Thursday no major side-effects were seen during their trial, apart from one person...WW…